グロフィタマブの新興医薬品に関する洞察と市場予測：2032年

グロフィタマブ（CD20-TCB、RG6026）は、B細胞表面のCD20とT細胞表面のCD3を標的とするように設計されたCD20xCD3 T細胞関与二特異性抗体です。グロフィタマブは「2：1」と呼ばれる新しい構造形式に基づいています。CD20に結合する2つの"Fab"領域とCD3に結合する1つの"Fab"領域を持つように設計されています。このデュアル・ターゲティングにより、患者の既存のT細胞が活性化され、B細胞に細胞傷害性タンパク質を放出することによって標的B細胞に関与し、排除するように方向転換されます。

現在、グロフィタマブの強力な臨床開発プログラムが進行中であり、DLBCLやMCLを含むB細胞性非ホジキンリンパ腫やその他の血液がんの治療薬として、単独療法や他の薬剤との併用療法を検討しています。

当レポートでは、主要7ヶ国におけるグロフィタマブ市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 DLBCLにおけるグロフィタマブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 グロフィタマブ市場評価

• DLBCLに対するグロフィタマブの市場展望
• 主要7ヶ国分析
  • 主要7ヶ国におけるDLBCLに対するグロフィタマブの市場規模
• 国別の市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Glofitamab, Clinical Trial Description, 2023
• Table 2: Glofitamab, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Glofitamab Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Glofitamab Market Size in the US, in USD million (2019-2032)
• Table 7: Glofitamab Market Size in Germany, in USD million (2019-2032)
• Table 8: Glofitamab Market Size in France, in USD million (2019-2032)
• Table 9: Glofitamab Market Size in Italy, in USD million (2019-2032)
• Table 10: Glofitamab Market Size in Spain, in USD million (2019-2032)
• Table 11: Glofitamab Market Size in the UK, in USD million (2019-2032)
• Table 12: Glofitamab Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Glofitamab Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Glofitamab Market Size in the United States, USD million (2019-2032)
• Figure 3: Glofitamab Market Size in Germany, USD million (2019-2032)
• Figure 4: Glofitamab Market Size in France, USD million (2019-2032)
• Figure 5: Glofitamab Market Size in Italy, USD million (2019-2032)
• Figure 6: Glofitamab Market Size in Spain, USD million (2019-2032)
• Figure 7: Glofitamab Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Glofitamab Market Size in Japan, USD million (2019-2032)

"Glofitamab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about glofitamab for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the glofitamab for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the glofitamab for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the glofitamab market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

Glofitamab (CD20-TCB, RG6026) is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. Glofitamab is based on a novel structural format called '2:1'. It is engineered to have two 'Fab' regions that bind to CD20 and one 'Fab' region, which binds to CD3. This dual targeting activates and redirects a patient's existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells.

A robust clinical development program for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines for treating people with B-cell NHL, including DLBCL and MCL, and other blood cancers.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the glofitamab description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on glofitamab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the glofitamab research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around glofitamab.
• The report contains forecasted sales of glofitamab for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for glofitamab in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Glofitamab Analytical Perspective by DelveInsight

In-depth Glofitamab Market Assessment

This report provides a detailed market assessment of glofitamab for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Glofitamab Clinical Assessment

The report provides the clinical trials information of glofitamab for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence glofitamab dominance.
• Other emerging products for DLBCL are expected to give tough market competition to glofitamab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of glofitamab in DLBCL.
• Our in-depth analysis of the forecasted sales data of glofitamab from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the glofitamab in DLBCL.

Key Questions:

• What is the product type, route of administration and mechanism of action of glofitamab?
• What is the clinical trial status of the study related to glofitamab in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the glofitamab development?
• What are the key designations that have been granted to glofitamab for DLBCL?
• What is the forecasted market scenario of glofitamab for DLBCL?
• What are the forecasted sales of glofitamab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to glofitamab for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

Table of Contents

1. Report Introduction

2. Glofitamab Overview in DLBCL

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Glofitamab Market Assessment

• 5.1. Market Outlook of Glofitamab in DLBCL
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Glofitamab in the 7MM for DLBCL
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Glofitamab in the United States for DLBCL
  • 5.3.2. Market Size of Glofitamab in Germany for DLBCL
  • 5.3.3. Market Size of Glofitamab in France for DLBCL
  • 5.3.4. Market Size of Glofitamab in Italy for DLBCL
  • 5.3.5. Market Size of Glofitamab in Spain for DLBCL
  • 5.3.6. Market Size of Glofitamab in the United Kingdom for DLBCL
  • 5.3.7. Market Size of Glofitamab in Japan for DLBCL

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options